Chardan raised the firm’s price target on Krystal Biotech (KRYS) to $220 from $216 and keeps a Buy rating on the shares. The company’s Q3 net Vyjuvek revenue topped estimates as results included a contribution from the recent launch in Germany, the analyst tells investors in a research note. Krystal has also reported an improved gross margin of 96% and “stable” gross-to-net ratio with previous quarters, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Positive Outlook for Krystal Biotech: Growth Potential Driven by Vyjuvek, Clinical Pipeline, and Global Expansion
- Krystal Biotech price target raised to $217 from $212 at Clear Street
- Krystal Biotech sees FY25 non-GAAP R&D, SG&A expense $145M-$155M
- Krystal Biotech reports Q3 EPS $2.66, consensus $1.12
- KRYS Earnings this Week: How Will it Perform?